Research memoSolventum Corporation (SOLV) · NYSEMemo of October 24, 2026By Olivier Lachance

Solventum stock forecast 2027–2029

MyStockButler's October 2026 analysis: Solventum's weighted forecast reaches $91.50 in October 2029, a 7% gain including dividends. It hinges on growth and cost improvement becoming dependable cash generation.

85.41
Share price today, USD
91.50 (+7%)
Weighted scenario, October 2029
11.6x
P/E, next 12 months
0.0%
Dividend yield
Read the full Solventum memoYour first S&P 500 report is free · no card
Every number traced to Solventum's filings8 chapters · 18,512 words206 sources cited

Where could Solventum's shares be by 2029?

The forecast points to weakness first, followed by a modest recovery. The weighted price is $73.16 in October 2027, a 14% loss including dividends. It reaches $81.92 in October 2028, a 4% loss. By October 2029, it reaches $91.50, a 7% gain.

Solventum share price scenarios for October 2029: bear $46.47, base $96.24, bull $147.19
What the shares could be worthUSD per share at each date; in brackets the return since today's 85.41, dividends included
CaseProbabilityOctober 2027October 2028October 2029
Bear30%50.03 (-41%)48.43 (-43%)46.47 (-46%)
Base50%76.24 (-11%)85.87 (+1%)96.24 (+13%)
Bull20%100.13 (+17%)122.25 (+43%)147.19 (+72%)
Weighted100%73.16 (-14%)81.92 (-4%)91.50 (+7%)

What this means. The weighted row is the probability-based average of the bear, base, and bull cases, not a promise that the shares will be worth that amount.

What has to go right, and what could go wrong for Solventum?

The bear case assumes that ERP order reversals reveal weaker demand, while litigation, separation costs and working capital keep cash conversion below earnings. Its price is $50.03 in October 2027 and $46.47 in October 2029. Its probability is 30% because free cash flow has been weak and 2026 guidance partly depends on tariff refunds, although all three segments grew organically in 2025.

The base case assumes moderate growth, easing costs and gradual productivity gains. Its price is $76.24 first and $96.24 last. Its probability is 50% because positive segment growth and current guidance support improvement, but the short standalone record and negative recent free cash flow limit confidence.

The bull case requires durable post-ERP demand, stronger wound-care adoption, faster savings and cash-funded debt reduction and buybacks. Its price is $100.13 first and $147.19 last. Its probability is 20% because several uncertain execution steps must succeed together.

How much cash does Solventum really make?

Adjusted earnings were approximately $702 million in the first half of 2026. Free cash flow consumed $129 million, producing approximately negative 18% conversion. Inventory, receivables, equipment purchases and separation payments can absorb cash even when accounting profit is positive.

The last eight quartersUS$ millions
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash from operations227-18996
− Capital spending838463
= Free cash flow144-27333

What this means. The revenue excludes the sold filtration business, but older profit and cash figures still include it, so those numbers are not directly comparable.

What does an investor pay for Solventum today?

What an investor pays todayUS$ millions
Today (Oct 24, 2026)
Share price85.41
Enterprise value (calculated)19,423.81
P/E, next 12 months (calculated)11.6x
EV / revenue, last 12 months (calculated)2.4x
Price to book (calculated)3.0x
Dividend yield (calculated)0.0%

What this means. Enterprise value is not just the stock-market value: it adds the company's debt and subtracts its cash to estimate what the whole business would cost.

From the full memo · 1. The business

Solventum sells medical and dental products used in everyday care, plus software that helps hospitals document treatment and get paid. Its dollar comes in through supplies, equipment use and software contracts, then goes out through manufacturing, service, distribution and the costs of operating a newly independent company.

Continue reading, free
Your first S&P 500 report is free · no card

Where these numbers come from

More on Solventum

Auf Deutsch

Its rivals

BD (BDX)Cardinal Health (CAH)STERIS (STE)Align (ALGN)

Browse

All stocksS&P 500 companiesCompanies SBloomberg Terminal alternatives
The full Solventum memoYour first S&P 500 report is free
Read it